Bottom Line: The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II ...

– Results highlight PPMP as a tool for identifying most promising drug combinations for patients in high unmet medical needs, including JMML – JMML is a rare, aggressive pediatric malignancy for which ...

Bottom line: The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II ...

Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic leukemia (CMML), a rare and aggressive form of blood cancer. The MEK inhibitor ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

At just six weeks old, Zeke Ramsey was diagnosed with Juvenile Myelomonocytic Leukemia — a rare form of leukemia with a survival rate of about 50%. Zeke, now healthy and five years old, joined the ...